Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Belgium France Germany Greece Italy Poland +3
  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Hungary Poland Portugal Romania Spain
  • Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

    Recruiting

    2 1 1
    Germany Italy Poland Romania Spain
  • A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Belgium France Italy The Netherlands Poland Spain
  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Austria Belgium Bulgaria Czechia Denmark France +11
  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1 1
    Poland
  • A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer

    Recruiting

    2 1 1
    Investigated drugs:
    France Italy Poland Romania Spain
  • A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    3 1 1
    Czechia France Germany Greece Hungary Italy +2
  • A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

    Recruiting

    1 1 1 1
    Germany Greece Hungary Italy Poland Spain
  • A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

    Recruiting

    2 1 1 1
    Finland Italy The Netherlands Poland Spain